<DOC>
	<DOCNO>NCT00629564</DOCNO>
	<brief_summary>This study look effect basal pentagastrin-stimulated acid output 40 mg Esomeprazole ( Nexium ) administer orally intravenously 15-minute infusion people symptoms Gastroesophageal Reflux Disease ( GERD )</brief_summary>
	<brief_title>An Open , Randomized , Two Way Crossover Study Comparing Effect 20mg Esomeprazole Administered Orally Intravenously 15 Minute Infusion Basal Pentagastrin-Stimulated Acid Output Subjects With Symptoms Gastroesophageal Reflux Disease ( GERD )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>1 . Heartburn least 2 day past 7 day prior screen , without history EE document diagnosis GERD within 6 month prior screen , without history EE . 2 . Body mass index ( BMI ) ≥18.5 ≤35 kg/m2 . [ BMI calculate use follow formula : weight ( kg ) /height ( ) 2 . ] 3 . Able communicate investigator understand comply requirement study . 1 . History esophageal , gastric , duodenal surgery , except simple closure ulcer . 2 . History severe liver disease , include ( limited ) cirrhosis acute chronic hepatitis . 3 . Any significant `` alarm symptom '' , within past 6 month , , unintentional weight loss , gastrointestinal bleeding , jaundice sign indicate serious malignant disease . 4 . Abnormal lab test result , indicate protocol . 5 . Other disease , indicate protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Gastroesophageal Reflux Disease ( GERD ) , esomeprazole , Nexium</keyword>
</DOC>